The short answer
MOTS-c appears in roughly 250 indexed PubMed records since 2015. Three papers anchor the field: the 2015 discovery in Cell Metabolism, the 2018 nuclear translocation finding, and the 2021 exercise study in Nature Communications. The literature is overwhelmingly preclinical, with human work largely observational.
Key facts
- Indexed PubMed records
- ~250
- First publication
- 3 March 2015
- Discovery paper
- PMID 25738459, Cell Metabolism
- Nuclear signalling
- PMID 29983246, Cell Metabolism 2018
- Exercise study
- PMID 33473109, Nature Communications 2021
- Evidence base
- Predominantly cell and rodent models
- Human data
- Largely observational
- Registered clinical trials
- None established for administration
The three anchor papers
The 2015 Cell Metabolism paper by Lee, Zeng, Drew and colleagues identified the peptide and reported its metabolic effects in mouse models. The 2018 Cell Metabolism paper by Kim, Son and Benayoun reported nuclear translocation under metabolic stress. The 2021 Nature Communications paper by Reynolds, Lai, Woodhead and colleagues reported exercise induction, with roughly 12-fold skeletal-muscle and 1.6-fold circulating increases in humans. Nearly everything else in the field builds on one of these three.
What kind of evidence this is
The great majority of the literature is preclinical: cultured cells and rodent models. Human involvement has largely taken the form of measuring endogenous concentrations and correlating them with age, fitness or metabolic state. That is a different category of evidence from an interventional trial, and the distinction governs what any of it can support.
Research material referenced
MOTS-C 10mg, third-party HPLC tested
Why correlation is the ceiling for the human data
Observing that circulating MOTS-c is lower in older or less metabolically healthy people establishes an association. It does not establish direction (the concentration could be a consequence of mitochondrial state rather than a cause of anything), and it certainly does not establish what administration would do. This is the inference the secondary literature most commonly overreaches on.
Where the newer work is going
More recent publications have examined mitochondrial respiration in disease models, including work on the diabetic heart, and on muscle mitochondrial bioenergetics in a PGC-1α/AMPK-dependent manner. These extend the mechanistic picture within the same preclinical frame rather than moving the evidence into a new category.
How to search it yourself
PubMed indexes the field under 'MOTS-c'. Filtering by publication type separates reviews from primary research, and checking the model organism in the abstract is the fastest way to establish what kind of evidence a given paper actually offers. Reviews are useful for orientation but inherit the limitations of what they summarise.
Frequently asked questions
Are there clinical trials of MOTS-c administration?
No established registered interventional trials of administration. The human literature measures endogenous concentrations rather than testing the peptide as an intervention.
Which paper should I read first?
The 2015 Cell Metabolism discovery paper, PMID 25738459. It establishes the peptide, its origin and its mechanism, and everything since references it.
Is 250 papers a large literature?
Modest. For comparison, well-established compounds accumulate thousands. It reflects a field roughly a decade old and still mostly preclinical.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedLee C et al., Cell Metabolism 2015 (PMID 25738459)pubmed.ncbi.nlm.nih.gov
- PubMedKim KH et al., Cell Metabolism 2018 (PMID 29983246)pubmed.ncbi.nlm.nih.gov
- PubMedReynolds JC et al., Nature Communications 2021 (PMID 33473109)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More MOTS-c (Mitochondrial Peptide) articles
- Mitochondria Read DNA DifferentlyAUA means methionine in mitochondria and isoleucine everywhere else. A 2008 PNAS paper argues the deviation exists to raise methionine content.
- The Residue That Oxidises So Others Do NotMethionine oxidation is usually called damage. It is also reversible, which makes methionine a regenerable antioxidant buffer rather than a liability.
- Two Methionines in Sixteen ResiduesMOTS-c is 12.5% methionine against roughly 2.3% across proteins generally - a five-fold enrichment, in a peptide from the genome whose code favours it.
- Why Mitochondrial Genetics Is Not Like Nuclear GeneticsCells carry many mitochondrial genomes, not two copies. Copy number and the mix of variants both vary, and both correlate with muscle oxidative capacity.
- A Class, Not a CompoundHumanin, MOTS-c and the SHLPs form a small family encoded within mitochondrial DNA. What reviews of the class establish, and what they concede.